Clinical Trials
44 trialsBevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation
Tianjin Medical University Cancer Institute and Hospital
UPLIFT
The First Affiliated Hospital of Guangzhou Medical University
CORIN
Sun Yat-sen University
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer
Betta Pharmaceuticals Co., Ltd.
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
Betta Pharmaceuticals Co., Ltd.
A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection
Peking University Cancer Hospital & Institute
ICAPE
Betta Pharmaceuticals Co., Ltd.
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
Liaoning Cancer Hospital & Institute
NeoIpower
Peking University Cancer Hospital & Institute
EVIDENCE
Betta Pharmaceuticals Co., Ltd.
ALTER-L004
Tianjin Medical University Cancer Institute and Hospital
SAINT
Tianjin Medical University Cancer Institute and Hospital
SMART
Betta Pharmaceuticals Co., Ltd.
Adjuvant Chemotherapy With or Without Intercalated Icotinib
Nanfang Hospital, Southern Medical University
High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases
Betta Pharmaceuticals Co., Ltd.
Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation
Betta Pharmaceuticals Co., Ltd.
Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC
China Medical University, China
BRAIN
Guangdong Association of Clinical Trials
High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC
ChineseAMS
Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation
ChineseAMS
First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation
Beijing Haidian Hospital
RT Plus EGFR-TKI for Wild-type NSCLC
Hangzhou Cancer Hospital
TCL-1
Qilu Hospital of Shandong University
First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients
Betta Pharmaceuticals Co., Ltd.
Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment
Betta Pharmaceuticals Co., Ltd.
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
Betta Pharmaceuticals Co., Ltd.
Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases
Betta Pharmaceuticals Co., Ltd.
Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency
Betta Pharmaceuticals Co., Ltd.
Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy
Betta Pharmaceuticals Co., Ltd.
Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy
Betta Pharmaceuticals Co., Ltd.
Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation
Betta Pharmaceuticals Co., Ltd.
High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease
Betta Pharmaceuticals Co., Ltd.
Chemotherapy of NSCLC With or Without Icotinib
Nanfang Hospital, Southern Medical University
Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer
People's Hospital of Guangxi Zhuang Autonomous Region
Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI
Betta Pharmaceuticals Co., Ltd.
Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer
Shandong Cancer Hospital and Institute
Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer
Zhejiang Cancer Hospital
Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose
Betta Pharmaceuticals Co., Ltd.
Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation
Betta Pharmaceuticals Co., Ltd.
ICOGEN
Betta Pharmaceuticals Co., Ltd.
Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer
Zhejiang Cancer Hospital